OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

20101,026 citationsJournal Articlebronze Open Access

Authors

SK Aurora · Swedish Medical Center

DW Dodick · Mayo Clinic Hospital

CC Turkel · Allergan (United States)

RE DeGryse · Allergan (Ireland)

SD Silberstein · Thomas Jefferson University

RB Lipton · Albert Einstein College of Medicine

HC Diener

Abstract

The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.

Topics & Keywords

Migraine and Headache Studies Sympathectomy and Hyperhidrosis Treatments Botulinum Toxin and Related Neurological Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cephalalgia

Volume 30, Issue 7, pp. 793-803

DOI: 10.1177/0333102410364676

Field-Weighted Citation Impact: 33.31